BACKGROUND: @entity3575 is a synthetic opioid, suitable for transdermal delivery, offering an interesting solution as a step 3 opioid in @entity5 treatment. The purpose of the study was to carefully investigate: 1) the feasibility of the direct conversion from @entity10425 to TTS @entity3575 , in @entity1 already receiving @entity10425 and requiring strong opioids for their @entity1337 ; 2) the safety of 25 microg/hour incremental steps and at shorter than 72-hour intervals, if clinically required. @entity1 AND METHODS: 130 @entity1 were judged eligible for the study. All the @entity1 were receiving 280-360 mg or more of @entity10425 and required strong opioid for their @entity1337 . The study lasted 56 days. The initial dose was 25 microg/hour. TTS @entity3575 for all @entity1 . Data assessments were made on baseline, day 1, day 2, day 3, in the hospital and thereafter on days 7, 14, 21, 28, 42 and 56. After the patch application, all the @entity1 were given an immediate release oral @entity1286 (5 mg) every 4-6 hours for the first 12 hours and then if needed only as rescue doses. The @entity1 remained in the hospital for the first three days of the study where follow-up ( @entity158 score, satisfaction, side effects etc.). was recorded by the palliative care team and by daily cards. RESULTS: The itnitial dose of @entity3575 was 25 microg/hour while the mean dose on day 3 was 45.9 microg/hour. All the @entity1 required upward titration of the study medication during follow-up visits. On day 56 the mean dose of @entity3575 was 87.4 microg/hour. Mean @entity158 intensity decreased from an initial 5.96 on the baseline to 0.83 on day 3. Karnofsky scale measurements between treatment phases revealed non-significant changes. The rate of overall satisfaction was quite high. Nine @entity1 discontinued the study due to inadequate @entity158 relief or side effects between day 7 and day 28, while five @entity1 died between day 28 and day 56. Constipation, @entity390 and @entity391 were the most common side effects. Skin reaction was relatively mild and acceptable during the study. CONCLUSION: Under controlled conditions, TTS @entity3575 seems to be feasible for direct conversion from mild to strong opioids and additionally, 25 microg/hour incremental steps day by day can be made by palliative care specialists, if clinically required for @entity5 management.

From @entity10425 to transdermal @entity3575 for XXXX control: a safety and efficacy clinical trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer pain'] @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity3575 :: ('MESH:D005283', 'Chemical') :: ['fentanyl', 'Fentanyl'] @entity10425 :: ('MESH:D003061', 'Chemical') :: ['codeine']
@entity5 :: (MESH:D009369,Disease) :: ['cancer pain']
